Oxaliplatin combined with continuous infusion of 5-fluorouracil as first-line chemotherapy in patients with metastatic or recurrent gastric adenocarcinoma

Chemotherapy

Volumn 55, Issue 4, 2009, Pages 200-206

  Lim, Jae Yun ^a   Cho, Jae Yong ^a   Oh, Kyung Jin ^a   Choi, Seung Ho ^a   Lee, Sang In ^a   Jeung, Hei Cheul ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Combination treatment; FOLFOX; Gastric cancer; Oxaliplatin

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; TAXANE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASIAN; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DEATH; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; ETHNIC GROUP; FATIGUE; FEMALE; GASTRECTOMY; HUMAN; INFECTION; INFECTIOUS COMPLICATION; KOREA; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OPEN STUDY; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; SIDE EFFECT; STOMACH ADENOCARCINOMA; STOMACH CARCINOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 65649104766     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000219434     Document Type: Article

References (25)

1. Jernal A, Thomas A, Murray T, Thun M: Cancer statistics 2002. CA Cancer J Clin 2002;52:23-47.
2. Bae JM, Won YJ, Jung KW, Park JG: Annual report of the Korean central cancer registry program 2000. Cancer Res Treat 2002;34:77-83.
3. Rivera F, Vega-Villegas ME, Lopez-Brea MF: Chemotherapy of advanced gastric cancer. Cancer Treat Rev 2007;33:315-324.
4. Van Cutsem E, Van de Velde C, Roth A, Lordick F, Köhne CH, Cascinu S, Aapro M, European Organisation for Research and Treatment of Cancer (EORTC) gastrointestinal cancer group: Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group. Eur J Cancer 2008;44:182-194.
5. Ajani JA: Standard chemotherapy for gastric carcinoma: is it a myth? J Clin Oncol 2000;18:4001-4002.
6. Bouché O, Raoul JL, Bonnetain F, Giovannini M, Etienne PL, Lledo G, Arsène D, Paitel JF, Guérin-Meyer V, Mitry E, Buecher B, Kaminsky MC, Seitz JF, Rougier P, Bedenne L, Milan C, Fédération Francophone de Cancerologie Digestive Group: Randomized multicenter phase II trial of a biweekly regimen offluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Fédération Francophone de Cancérologie Digestive Group Study - FFCD 9803. J Clin Oncol 2004;22:4319-4328.
7. Roth AD, Ajani JA: Docetaxel-based chemotherapy in the treatment of gastric cancer. Ann Oncol 2003;14(suppl 2):ii41-ii44.
8. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T: Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 Mtegafur-0.4M gimestat-1 Motastat potassium) in advanced gastric cancer patients. Eur J Cancer 1998;34:1715-1720.
9. Louvet C, André T, Tigaud JM, Gamelin E, Douillard JY, Brunet R, François E, Jacob JH, Levoir D, Taamma A, Rougier P, Cvitkovic E, de Gramont A: Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol 2002;20:4543-4548.
10. Woynarowski JM, Faivre S, Heizig MC, Arnett B, Chapman WG, Trevino AV, Raymond E, Chaney SG, Vaisman A, Varchenko M, Juniewicz PE: Oxaliplatin-induced damage of cellular DNA. Mol Pharmacol 2000;58:920-927.
11. Sekiguchi M, Eriguchi M, Shiroko Y, Mikamo S: Chemosensitivity screening in vitro of various cultured human cancer cell lines to a new platinum complex, 1-OHP; oxalate (trans-1-1, 2-diaminocyclohexane)platinum (iI). Ann Oncol 1992;3:AP107-AP194.
12. De Vita F, Orditura M, Matano E, Bianco R, Carlomagno C, Infusino S, Damiano V, Simeone E, Diadema MR, Lieto E, Castellano P, Pepe S, De Placido S, Galizia G, Di Martino N, Ciardiello F, Catalano G, Bianco AR: A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br J Cancer 2005;92:1644-1649.
13. Al-Batran SE, Atmaca A, Hegewisch-Becker S, Jaeger D, Hahnfeld S, Rummel MJ, Seipelt G, Rost A, Orth J, Knuth A, Jaeger E: Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol 2004;22:658-663.
14. Oh SY, Kwon HC, Seo BG, Kim SH, Kim JS, Kim HJ: A phase II study of oxaliplatin with low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) as first line therapy for patients with advanced gastric cancer. Acta Oncol 2007;46:336-341.
15. Lordick F, Lorenzen S, Stollfuss J, VehlingKaiser U, Kullmann F, Hentrich M, Zumschlinge R, Dietzfelbinger H, Thoedtmann J, Hennig M, Seroneit T, Bredenkamp R, Duyster J, Peschel C: Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer. Br J Cancer 2005;93:190-194.
16. Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, Rethwisch V, Seipelt G, Homann N, Wilhelm G, Schuch G, Stoehlmacher J, Derigs HG, Hegewisch-Becker S, Grossmann J, Pauligk C, Atmaca A, Bokemeyer C, Knuth A, Jäger E, Arbeitsgemeinschaft Internistische Onkologie: Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2008;26:1435-1442.
17. Hwang WS, Chao TY, Lin SF, Chung CY, Chiu CF, Chang YF, Chen PM, Chiou TJ: Phase II study of oxaliplatin in combination with continuous infusion of 5-fluorouracil/ leucovorin as first-line chemotherapy in patients with advanced gastric cancer. Anti-cancer Drugs 2008;19:283-288.
18. Keam B, Im SA, Han SW, Ham HS, Kim MA, Oh DY, Lee SH, Kim JH, Kim DW, Kim TY, Heo DS, Kim WH, Bang YJ: Modified FOLFOX-6 chemotherapy in advanced gastric cancer: results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker. BMC Cancer 2008;8:148.
19. Luo HY, Xu RH, Zhang L, Li YH, Shi YX, Lin TY, Han B, Wang F, Qiu MZ, He YJ, Guan ZZ: A pilot study of oxaliplatin, fluorouracil and folinic acid (FOLFOX-6) as first-line chemotherapy in advanced or recurrent gastric cancer. Chemotherapy 2008;54:228-235.
20. Giuliani F, Gebbia V, De Vita F, Maiello E, Di Biscelie M, Catalano G, Gebbia N, Collucci G: Docetaxel as salvage therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico Italia Meridionale (G.O.I.M.). Anticancer Res 2003;23:4219-4222.
21. Satoh S, Kawashima K, Matsumoto S, Hasegawa S, Okabe H, Nomura A, Yoshibayashi H, Watanabe G, Nagayama S, Fukushima M, Sakai Y: Retrospective evaluation of sequential outpatient chemotherapy for advanced gastric cancer. Chemotherapy 2007;53:226-232.
22. Cvitkovic E, Bekradda M: Oxaliplatin: a new therapeutic option in colorectal cancer. Semin Oncol 1999;26:647-662.
23. Pinotti G, Martinelli B: A case of acute tubular necrosis due to oxaliplatin. Ann Oncol 2002;13:1951-1952.
24. Labaye J, Sarret D, Duvic C, Hérody M, Didelot F, Nédélec G, Noël LH: Renal toxicity of oxaliplatin. Nephrol Dial Transplant 2005;20:1275-1276.
25. Cavanna L, Artioli F, Codignola C, Lazzaro A, Rizzi A, Gamboni A, Rota L, Rodinò C, Boni F, Iop A, Zaniboni A: Oxaliplatin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in patients with metastatic gastric cancer (MCC). Am J Clin Oncol 2006;29:371-175